Filtered By:
Condition: Hemorrhagic Stroke
Countries: USA Health

This page shows you your search results in order of relevance. This is page number 4.

Order by Relevance | Date

Total 190 results found since Jan 2013.

Age-Related Disparity Trends in Stroke-Related Mortality in the United States, 1999 to 2019
Stroke hospitalizations and mortality have declined in older subjects in the United States; however, acute ischemic stroke hospitalizations have increased in subjects 25 to 64  years of age.1,2 Regardless of increasing acute ischemic stroke hospitalization trends in young patients, population-based estimates and trends of stroke (including hemorrhagic and ischemic stroke) related mortality stratified by age groups are currently scarce. Therefore, in this study, we assess ed trends in stroke mortality rates in varying age groups over 2 decades in the United States.
Source: The American Journal of Cardiology - February 28, 2022 Category: Cardiology Authors: Rochell Issa, Abdul Mannan Khan Minhas, Robert W. Ariss, Salik Nazir, Hiba Rehman, Waleed Tallat Kayani, Salim S. Virani Source Type: research

Pre-stroke glycemia in patients with diabetes
Conclusion Insulin treatment and hyperlipidemia are associated with higher HbA1c levels in acute stroke patients with T2D. Poor adherence to diabetes treatment is associated with higher HbA1c levels only among patients with HbA1c ≥8%.
Source: Diabetes and Metabolic Syndrome: Clinical Research and Reviews - July 4, 2017 Category: Endocrinology Source Type: research

Left ventricular hypertrophy in acute stroke patients with known hypertension.
CONCLUSIONS: In acute stroke patients, poor adherence to hypertension treatment is a significant independent predictor of LVH. A clear reason for poor adherence to treatment is elusive in a large proportion of these patients in our study. Further research is needed to identify and develop strategies to combat the key factors responsible for poor adherence to hypertension treatment. PMID: 28722487 [PubMed - as supplied by publisher]
Source: Clinical and Experimental Hypertension - July 19, 2017 Category: Cardiology Authors: Bruno A, Brooks DD, Abrams TA, Poorak MD, Gunio D, Kandhal PK, Lakhanpal A, Nagabandi AK, Akinwuntan AE, Looney S, Schafer PE Tags: Clin Exp Hypertens Source Type: research

Expansion of the dimensions in the current management of acute ischemic stroke
AbstractStroke is the fifth leading cause of death in the United States with a huge burden on health care. Acute ischemic stroke (AIS) accounts for 87% of all stroke. The use of thrombolytic agents in AIS treatment is well known since 1950 but no FDA approval until 1996, due to lack of strong evidence showing benefits outweigh the risk of intracranial hemorrhage. The NINDS trial led to the approval of intravenous tissue plasminogen activator treatment (IV recombinant tPA) within 3  h of stroke. Due to this limitation of 3–4.5 h. window, evolution began in the development of effective endovascular therapy (EVT). Multipl...
Source: Journal of Neurology - May 19, 2020 Category: Neurology Source Type: research

E-006 Feasibility and safety of mechanical thrombectomy in stroke patients presenting with distal ACA occlusions - insights from star
ConclusionIn this multicenter study, MT for distal ACA occlusions in the A2/A3 segments seem to be feasible and associated with low complication and symptomatic hemorrhage rates. Future studies are needed to compare the functional outcome of MT versus medical management for stroke patients presenting with A2/A3 occlusions.Disclosures D. Pullmann: None. E. Almallouhi: None. S. Al Kasab: None. A. Alawieh: None. R. Chalhoub: None. R. Starke: None. R. De Leacy: None. D. Raper: None. A. Rai: None. T. Dumont: None. S. Wolfe: None. P. Jabbour: None. C. Ogilvy: None. M. Park: None. M. Levitt: None. A. Polifka: None. R. Crowley: No...
Source: Journal of NeuroInterventional Surgery - July 26, 2021 Category: Neurosurgery Authors: Pullmann, D., Almallouhi, E., Al Kasab, S., Alawieh, A., Chalhoub, R., Starke, R., De Leacy, R., Raper, D., Rai, A., Dumont, T., Wolfe, S., Jabbour, P., Ogilvy, C., Park, M., Levitt, M., Polifka, A., Crowley, R., Arthur, A., Osbun, J., Crosa, R., Maier, I Tags: Electronic poster abstracts Source Type: research

E-096 COVID status is related to clot burden during thrombectomy in acute stroke patients
ConclusionOf 230 patients included in this interim analysis across 24 centers in the United States, between 02/2021 and 01/2022, 16 patients had a history of COVID. Comparing COVID-positive to non-positive, patients with COVID were younger (median 66.5 years vs 71.5 years, p 0.042), and had more intracranial clot by weight (median 101.0 mg vs 42.0 mg, p 0.047). There was a trend toward COVID positive patients to have more clot volume (median 180 cc vs 77.5 cc p 0.08), suggesting the difference was a higher clot burden instead of more density to the thrombus. These results suggest different histopathological characteristics...
Source: Journal of NeuroInterventional Surgery - July 23, 2022 Category: Neurosurgery Authors: Fraser, J., Dabney, A., Vicari, J., Rivet, D., Woodward, B., Nanda, A., Fiorella, D., Baltan, S., Sohrabji, F., Pennypacker, K., Kellner, C. Tags: SNIS 19th annual meeting electronic poster abstracts Source Type: research

Citation Classics in Stroke: The Top-100 Cited Articles on Hemorrhagic Stroke
Conclusions: We analyzed the top-100 cited articles in the field of HS based on citation rates. The results provide a unique perspective on historical and academic developments in this field.Eur Neurol 2017;78:210 –216
Source: European Neurology - September 14, 2017 Category: Neurology Source Type: research

Indications and Evidence for Dual Antiplatelet Therapy After Acute Ischemic Stroke
The antiplatelet landscape for the secondary prevention of ischemic stroke has changed significantly over the past decade. Poststroke dual antiplatelet regimens are becoming increasingly routine as supported by recent literature and guideline recommendations. Dual antiplatelet therapy after stroke generally consists of aspirin and clopidogrel and is considered in the short term after stroke in select populations including those with mild stroke or transient ischemic attack and in patients with severe intracranial atherosclerosis. When initiating dual antiplatelet therapy, factors that may increase a patient's risk of bleed...
Source: Critical Care Nursing Quarterly - February 22, 2020 Category: Nursing Tags: Original Articles Source Type: research

Stroke Treatment With PAR-1 Agents to Decrease Hemorrhagic Transformation
Ischemic stroke is the most widespread cause of disability and a leading cause of death in developed countries. To date, the most potent approved treatment for acute stroke is recanalization therapy with thrombolytic drugs such as tissue plasminogen activator (rt-PA or tPA) or endovascular mechanical thrombectomy. Although tPA and thrombectomy are widely available in the United States, it is currently estimated that only 10–20% of stroke patients get tPA treatment, in part due to restrictive selection criteria. Recently, however, tPA and thrombectomy selection criteria have loosened, potentially allowing more patients to...
Source: Frontiers in Neurology - March 15, 2021 Category: Neurology Source Type: research

Apparent Treatment-Resistant Hypertension Among Stroke Survivors: A Transcontinental Study assessing impact of race and geography
CONCLUSIONS: Future studies are needed to investigate the contribution of socioeconomic disparities in the prevalence aTRH in those with African Ancestry to explore the long-term impact, and evaluate effective therapeutic interventions in this subpopulation.PMID:35366323 | DOI:10.1093/ajh/hpac046
Source: American Journal of Hypertension - April 2, 2022 Category: Cardiology Authors: Fred Stephen Sarfo Esther Olasoji Grant P Banfill Bruce Ovbiagele Alexis N Simpkins Source Type: research

Mechanical thrombectomy beyond the circle of Willis: efficacy and safety of different techniques for M2 occlusions
Conclusion Stent-retrievers and a combined approach for M2 occlusions seem more effective than direct aspiration, but with higher rates of iSAH. This leads to no detectable difference in clinical outcome at 3 months.
Source: Journal of NeuroInterventional Surgery - May 13, 2022 Category: Neurosurgery Authors: Renieri, L., Valente, I., Dmytriw, A. A., Puri, A. S., Singh, J., Nappini, S., Nencini, P., Kaliaev, A., Abdalkader, M., Alexandre, A., Garignano, G., Vivekanandan, S., Fong, R. P., Parra-Farinas, C., Spears, J., Gomez-Paz, S., Ogilvy, C., Regenhardt, R. Tags: Ischemic stroke Source Type: research

Teleneurocritical Care for Patients with Large Vessel Occlusive Ischemic Stroke Treated by Thrombectomy
ConclusionsTeleneurocritical care allows for equivalent favorable functional outcomes compared with in-person neurocritical care for patients with acute large vessel ischemic stroke receiving thrombectomy. The standardized protocols used by TNCC in this study, specifically the comprehensive 24/7 treatment of patients in the intensive care unit for the length of their stay, may be relevant for other health systems with limited in-person resources; however, additional study is required.
Source: Neurocritical Care - November 2, 2022 Category: Neurology Source Type: research